NEW YORK – Adaptive Biotechnologies and lab services provider Q2 Solutions said on Monday that they will partner to market Adaptive's ImmunoSeq assay.
Under the terms of the agreement, Q2 Solutions will offer its customers ImmunoSeq, a next-generation sequencing-based assay that analyzes immune cell receptors, as well as ImmunoSeq T-Map COVID, a research product and data analysis service that can assess T cell response to COVID-19 vaccines in development and track the persistence of the immune response over time.
Q2 Solutions will run studies for its pharma and biotech clients using both blood and tumor tissue sample matrices. It will also use Adaptive's proprietary bioinformatics pipeline to perform analytical testing and data analysis before releasing results to pharma customers.
Financial and other terms of the deal were not disclosed.
"These new genomics services will further expand our global immuno-oncology and COVID-19 comprehensive testing portfolio solutions offered to our pharma clients," Patrice Hugo, Q2 Solutions' CSO, said in a statement.
Launched in 2015 as a joint venture of IQvia and Quest Diagnostics, Q2 Solutions provides clinical trials research services.
Announced in March, ImmunoSeq T-Map COVID provides researchers with a quantitative map of T-cell receptors specific for SARS-CoV-2 antigens that are driving the immune response to vaccines and other therapies in development for COVID-19. It is powered by ImmuneCode, a database developed in partnership with Microsoft.
Seattle-based Adaptive is also working on T-Detect COVID, a diagnostic version of the ImmunoSeq assay for COVID-19.